Pain may be caused by inflammation or dysfunctional nerves. Neuropathic pain arises from a damaged nerve or impaired central nervous system (CNS), which is comprised of the brain and spinal nerves. The spinal nerves carry pain signals from the body to the brain via sodium and calcium channels. Accumulation of excessive sodium or calcium channels can lead to spontaneous firing of sensory nerves, resulting in prolonged chronic pain.
Prescription medications include anticonvulsants, corticosteroids, muscle relaxers, nerve blocks, NSAIDs, and opioids, all of which tend to have many undesirable side effects. Membrane-stabilizing medications include local anesthetics, steroids, and anticonvulsants,
which block sodium and calcium channels in nerve cells, reducing the pain signaling.
QuantumActiv™ ParActin® is a natural calcium channel blocker that provides powerful, fast-acting joint and muscle comfort without a prescription. The patented QuantumActiv™ skin delivery system effectively penetrates the skin to quickly deliver targeted relief when applied to affected areas.
This FDA-approved topical analgesic contains 1.5% menthol for the temporary relief of minor aches and pains of sore muscles and joints, associated with arthritis, backaches, strains, bruises, sprains, and sports injuries. Continued use of the product may significantly help to increase range of motion, flexibility, and mobility.
QuantumActiv™ ParActin® Instant Pain Relief Cream can be marketed as a pre-workout and post-workout sport cream without menthol. When applied 15 minutes prior to exercise or strenuous activities, the product improves range of motion and flexibility, and helps to reduce sprains, muscle aches, and sport injuries.
ParActin®’s inflammation-management activity comes through its proven ability to switch on the PPAR-gamma receptor, which inhibits an inflammatory molecule, NF-kB, the key regulator of our immune response system.
This reduces a family of pro-inflammatory cytokines such as IL-1b, IL-6, TNF-a, COX-2 and iNOS. Research has shown that ParActin® can selectively block voltage-operated calcium channels and inhibit the entry of Ca(+2) influx, thereby reducing the firing of pain sensation in the neurons.
5 Times More Potent In COX-2 Inhibition
Experimental osteoarthritis (OA) was induced in rats with a knee injection of Monosodium Iodoacetate (MIA). Andrographis paniculata extract (APE) substantially reversed the loss of hind limb weight-bearing in the rats, which translates to a pain-relieving effect in the osteoarthritic knees. In addition APE prevented cartilage damage resulted from
the OA induction in rats.
These results are comparable to indomethacin. Acetic acid-induced writhing is used to evaluate analgesic effects of APE and to quantitatively measure inflammatory pain.
Rats fed with 1000 mg/kg of APE had average writhing number of 67.22%, comparable to ibuprofen group 58.09%. This result suggests high efficacy of APE in suppressing peripheral pain.
APE administrated rats had a significant reduction in the concentration of IL-1, IL-6, and TNF-⍺ in comparison with the control group. 300 μg/mL APE reduced the cytokine levels comparable to 1ug/mL of dexamethasone.
Mechanical sensitivity was determined by measuring the withdrawal thresholds, and response percentage to von Frey hairs. The withdrawal thresholds of the right and left hind paw in the OP-Andro group were significantly higher compared with OP-saline group and OP-NSAIDs group. Andro reduced the neurological pain.
Andrographis paniculata (AP) selectively blocks voltage-operated calcium channels in rat vas deferens. 0.4mg/ml of AP and 1X10-7 M of Verapamil significantly reduced the KCl induced influx of 45Ca2, selectively blockades voltage-operated calcium channels (VOCs), hence inhibiting the 45Ca2 Influx, without affecting the response of norepinephrine.
HP Ingredients offers custom formulations and private labeling services to manufacturers. HPI’s innovation in formulations is accomplished by combining our trademarked ingredients with other clinically tested, well-researched nutraceuticals.